glp 1(7 37)

GLP-1 (7-37) is a truncated, bioactive form of GLP-1 that is the product of proglucagon processing in intestinal endocrine L cells.

Glp-1(7-37) acetate is an intestinal insulin hormone that enhances glucose-induced insulin secretion.

GLP-1(7-36), amide (MKC 253) is a peptide hormone released from intestinal L-cells upon nutrient consumption. It binds the GLP-1 receptor in the pancreas and displays various antidiabetic effects by potentiating glucose-induced secretion of insulin from pancreatic β-cells, increasing insulin expression.

Tripeptide-1 Acetate is a biologically active peptide

GLP-1(32-36)amide acetate is a pentapeptide and derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide acetate could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice.

Hemokinin 1 (human) acetate is an endogenous substance P homolog that is a selective agonist at the tachykinin NK1 receptor (IC50 values are 1.8, 370 and 480 nM for NK1, NK3 and NK2 receptors respectively). Has proliferative and antiapoptotic actions on B

Substance P (1-7) 2TFA(68060-49-1(free base)) is the major bioactive metabolite formed after proteolytic degradation of the tachykinin substance P (SP),with anti-inflammatory, anti-nociceptive and anti-hyperalgesic effects

Nociceptin (1-7) acetate is a potent agonist of opioid receptor-like 1 (ORL1) receptor. Nociceptin (1-7) combines with nociceptin reduces hyperalgesia and has antinociceptive activity.

GLP-1(28-36)amide acetate inhibits mitochondrial permeability transition with antioxidant, anti-diabetic and cardioprotection activities.

Angiotensin 1/2 (5-7) acetate is a peptide with the sequence H2N-Ile-His-Pro-OH. Angiotensin is an oligopeptide and is a hormone and a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It

LL-37, Human acetate is a 37-residue, amphipathic, cathelicidin-derived antimicrobial peptide, which exhibits a broad spectrum of antimicrobial activity.

Orphanin FQ(1-11) acetate(178249-41-7 free base) is a peptide fragment containing amino acids 1-11 of Nociceptin. Orphanin FQ(1-11) acetate(178249-41-7 free base) is a potent agonist of the ORL1/KOR-3 receptor (Ki = 55 nM) and displays no affinity for opioid receptors, including μ, δ, κ1 and κ3 receptors (Ki >1000 nM). Orphanin FQ(1-11) acetate(178249-41-7 free base) displays analgesic properties in CD-1 mice.

Substance P(1-7) (Substance P 1-7) is the major bioactive metabolite formed after proteolytic degradation of the tachykinin substance P (SP),with anti-inflammatory, anti-nociceptive and anti-hyperalgesic effects

Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.Pancreatic hormone synthesized by post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it has no effect on food intake in rats and does not en

GLP-2(1-33) (human) is an enteroendocrine hormone which stimulates the growth of the intestinal epithelium.

PTH-Related Protein (1-37) (human, mouse, rat) is a peptide analog of parathyroid-hormone-related protein (pTHrP), which plays a role in the physiological regulation of bone formation [1].

GLP-2 (1-34) (human), a polypeptide secreted from the intestine shortly after eating, is utilized in research related to bone remodeling processes [1].

GLP-1(28-36)amide, a C-terminal nonapeptide derived from the cleavage of GLP-1 by neutral endopeptidase (NEP), is a significant product. It functions as an antioxidant and primarily targets the mitochondrion, where it effectively inhibits mitochondrial permeability transition (MPT). This compound exhibits anti-diabetic properties and demonstrates cardioprotection effects[1].

Human LL-37 is a 37 amino acid cationic (6+) peptide and has been widely studied. LL-37 penetrates the bacterial membrane and forms pores in the membrane.

Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP(1-7)-GRF(8-27) is a selective antagonist [1] for the vasoactive intestinal peptide 1 (VIP 1) receptor.

Bradykinin (1-7), an amino-truncated peptide derived from Bradykinin, is a metabolite formed through enzymatic cleavage by endopeptidase.

GLP-1 (1-36) amide (human, rat) TFA, a molecular variant of GLP-1 (7-36) amide, can induce [14C]aminopyrine accumulation in enzymatically dispersed enriched rat parietal cells [1].

Glucagon-like peptide 1 (1-37), human acetate is a highly potent the GLP-1 receptor agonist.

α-Bag Cell Peptide (1-7) is an amino-terminal fragment of the α-bag cell peptide that possesses the ability to inhibit neurons in the left upper quadrant (LUQ) and prevent the depolarization of the bag cells [1].

[K15,R16,L27]VIP(1-7)/GRF(8-27), a selective agonist for the VIP 1 receptor, demonstrates binding IC 50 values of 2 nM for the human VIP 1, 1 nM for the rat VIP 1, and 30,000 nM for the rat VIP 2 receptors, respectively [1]. VIP stands for VASOACTIVE Intestinal Polypeptide.

[K15,R16,L27]VIP(1-7)/GRF(8-27) (acetate) is an acetate salt form of the peptide [K15,R16,L27]VIP(1-7)/GRF(8-27). This compound acts as a selective agonist for the VIP 1 receptor, displaying IC50 values of 2 nM for human VIP 1, 1 nM for rat VIP 1, and 30,000 nM for rat VIP 2 receptors [1]. The peptide's acronym, VIP, stands for Vasoactive Intestinal Polypeptide.

Substance P(1-7) TFA, a fragment of the neuropeptide substance P (SP), induces depressor and bradycardic effects upon application to the nucleus tractus solitarius [1].

GLP-1(32-36)amide TFA, originating from the C-terminal end of the glucoregulatory hormone GLP-1, is a pentapeptide that has demonstrated the ability to mitigate weight gain and regulate glucose metabolism throughout the body in diabetic mice [1] [2].

Kaliotoxin (1-37), a toxin derived from the scorpion Androctonus mauretanicus mauretanicus, acts as a potent blocker of calcium-dependent potassium channels [1].

Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor, it is a kind of pancreatic hormone synthesized by post-translational processing of proglucagon.

Angiotensin 1-7 (Ang-(1-7)) acetate, an endogenous heptapeptide from the renin-angiotensin system (RAS), exhibits cardioprotective effects through its anti-inflammatory and anti-fibrotic activities in cardiac cells. It effectively inhibits purified canine ACE activity (IC 50 =0.65 μM) and serves as a local synergistic modulator of kinin-induced vasodilation by hindering ACE and facilitating nitric oxide release. Additionally, this compound prevents Ang II-induced proliferation and hypertrophy in smooth muscle cells, alongside demonstrating antiangiogenic and growth-inhibitory effects on the endothelium [1] [2] [3].

GLP-1 (1-36) amide (human, rat) is a molecular variant of the GLP-1 (7-36) amide and has the capacity to stimulate [14C]aminopyrine accumulation in enzymatically dispersed, enriched rat parietal cells [1].

GLP-1(7-36), amide TFA is a prominent intestinal hormone known to stimulate glucose-induced insulin secretion from β cells[1].

Angiotensin (1-7) (ASP-ARG-VAL-TYR-ILE-HIS-PRO) is a synthetic heptapeptide identical to endogenous angiotensin-(1-7) , inhibits purified canine ACE activity (IC50=0.65 μM) with vasodilator and antiproliferative activities.

Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human, is a human GLP-1 (7-36) amide that has been biotinylated at the C-terminal.

(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide-1 amide originating from glucagonogen, itself a cleavage product of the GLP-1 (1-36) amide peptide. This entero-insulinotropic hormone facilitates glucose-dependent insulin secretion from pancreatic β-cells and influences gastrointestinal motility and secretion [1].

GLP-1(7-36) Acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

antagonist at the human GLP-1 receptor

Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide, a biotin-labeled variant of glucagon-like peptide-1-(7-36), is a gastrointestinal peptide recognized for its antidiabetogenic properties, including the ability to enhance insulin secretion [1] [2].

Cecropin A (1-7)-Melittin A (2-9) is an antimicrobial peptide that exhibits broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative aerobic bacteria, in addition to antimalarial properties. Notably, it does not possess the adverse hemolytic effects commonly associated with bee venom peptides [1].

pTH (1-37) (human), a fragment of parathyroid hormone (PTH), promotes cAMP formation and enhances alkaline phosphatase activity. Additionally, it fosters growth, elevates bone calcium content, and augments bone mineral density (BMD) in uremic animals. This compound shows promise for osteoporosis research [1] [2] [3].

GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide which is a glucagon-like peptide 1 receptor (GLP-1) agonist.

GLP-1 amide is a peptide hormone cleaved from proglucagon in the pancreas.1,2 Mice lacking the glucagon receptor (Gcgr-/-) have approximately nine-fold higher levels of total GLP-1 amide, including GLP-1 (1-36) amide and truncated GLP-1 (7-36) amide , in pancreatic tissue compared to wild-type mice.2References1. Schjoldager, B.T., Mortensen, P.E., Christiansen, J., et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 34(5), 703-708 (1989).2. Gelling, R.W., Du, X.Q., Dichmann, D.S., et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100(3), 1438-1443 (2003). GLP-1 amide is a peptide hormone cleaved from proglucagon in the pancreas.1,2 Mice lacking the glucagon receptor (Gcgr-/-) have approximately nine-fold higher levels of total GLP-1 amide, including GLP-1 (1-36) amide and truncated GLP-1 (7-36) amide , in pancreatic tissue compared to wild-type mice.2 References1. Schjoldager, B.T., Mortensen, P.E., Christiansen, J., et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 34(5), 703-708 (1989).2. Gelling, R.W., Du, X.Q., Dichmann, D.S., et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 100(3), 1438-1443 (2003).

Amylin (1-37) (human) (hIAPP (1-37)), a peptide hormone found in pancreatic beta-cell secretory granules, features an amidated C-terminus and a disulfide bond between cysteine residues 2 and 7 [1].

GLP-1(28-36)amide TFA, a C-terminal nonapeptide derived from GLP-1 cleavage by neutral endopeptidase (NEP), acts as an antioxidant targeting mitochondria. It inhibits mitochondrial permeability transition (MPT), exhibiting anti-diabetic and cardioprotective effects [1].

GLP-1(9-36)amide TFA, a predominant metabolite of glucagon-like peptide-1-(7-36)amide synthesized through dipeptidyl peptidase-4 (DPP-4) activity, functions as an antagonist to the human pancreatic GLP-1 receptor [1] [2].

Bioactive metabolite of nociceptin, antagonist of nociceptin-induced hyperalgesia

Substance P (1-7)(TFA) is a fragment of the neuropeptide, substance P (SP).

β-Amyloid (1-37) (human) Potentially associated with mental status in Alzheimer's disease.

Nociceptin (1-7) TFA, the N-terminal bioactive fragment of nociceptin, serves as a potent ORL 1 (NOP) receptor agonist, exhibiting antinociceptive properties. Its combination with nociceptin effectively reduces hyperalgesia in vivo [1].